PRESS RELEASES

Altasciences is committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.

The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.

James Brazeal has joined Altasciences' as General Manager, Clinical Operations, of our Kansas City facility. Read more about James here.

Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. The impressive 8,000-square-foot space features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.

Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray, GCPQ, under the trade name, AnQlar. Click to read more.

Altasciences is pleased to have completed the successful Phase I trial of Ischemix’ novel drug candidate, CMX-2043, for the treatment of acute traumatic brain injury (TBI), at our Montréal clinical facility.